Medication info

Shubatan Tablet 10 mg (Rosuvastatin Calcium)

Prescription medicationTabletExpired
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Mirae Bio Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
For domestic use (30 tablets) - 30 tablets/bottle, For domestic use (100 tablets) - 100 tablets/bottle
Approval status
Expired

MFDS item code 201403830 · Approved 2014.08.19

This product's status changed to Expired on 2024.08.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of dyslipidemia; inhibition of atherosclerosis progression; reduction of cardiovascular disease risk
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted as a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 milligrams once daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of this drug is contraindicated in some of these patients.
Children's dosage
Age 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses above 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Mirae Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia; inhibition of atherosclerosis progression; reduction of cardiovascular disease risk

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary artery disease
  • stroke
  • myocardial infarction
View approved original text

This medication aids patients with primary hypercholesterolemia and mixed dyslipidemia when dietary measures and exercise alone are insufficient. It is also used as an adjunct to diet for patients with homozygous familial hypercholesterolemia. It lowers total cholesterol and LDL cholesterol levels, thereby delaying the progression of atherosclerosis. It is used as a dietary adjunct to reduce cholesterol levels in pediatric patients aged 10 to 17 with familial hypercholesterolemia. It is also used in patients with primary dysbetalipoproteinemia. Particularly in middle-aged individuals with high-sensitivity C-reactive protein levels and at risk of cardiovascular disease, it helps lower the risk of stroke, myocardial infarction, and vascular revascularization. This medication is used to improve cholesterol levels and reduce the risk of cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted as a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 milligrams once daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of this drug is contraindicated in some of these patients.

Children's dosage

Age 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses above 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For example, individuals allergic to any ingredients of this drug, those with severely impaired liver function, those with muscle diseases, those taking specific medications concomitantly, those with severely impaired kidney function, pregnant or breastfeeding women, and those with certain genetic disorders should not take this medication. Caution should be exercised in patients with a history of excessive alcohol consumption or liver disease. Liver function tests should be routinely performed before and during treatment. Patients with hypercholesterolemia due to hypothyroidism or nephrotic syndrome should treat the underlying cause before using this medication. Muscle-related side effects such as myalgia or myopathy, and rarely serious muscle destruction known as rhabdomyolysis, may occur; any unusual muscle symptoms should be reported to a healthcare professional immediately. If there is a significant increase in muscle enzyme levels, this medication should be discontinued, and it may be restarted at a lower dose once symptoms improve. This medication contains lactose, so patients with lactose intolerance should not take it. It may affect liver and kidney function, so regular monitoring of liver and kidney function is necessary. Additionally, blood sugar levels may increase in some patients; hence, those at risk of diabetes should regularly check their blood glucose levels. This drug may interact with other medications, so patients must inform their healthcare provider of all concurrent medications. Special attention is needed when used with drugs that increase the risk of muscle toxicity, and the use of some medications concomitantly is prohibited. Women who are pregnant or may become pregnant should not take this medication and should use effective contraception. Nursing mothers are also advised not to take this medication. There is no specific antidote in case of overdose, so treatment will be symptomatic, along with monitoring of liver function and muscle enzyme levels. This medication is not known to significantly affect the ability to drive or operate machinery, but caution is advised as dizziness may occur. Lastly, if severe rashes or allergic reactions occur during treatment with this drug, use should be discontinued immediately and a healthcare provider should be consulted.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, urticarial drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is advisable to keep it at room temperature, between 1 to 30 degrees Celsius, avoiding extremely hot or cold environments.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

For domestic use (30 tablets) - 30 tablets/bottle, For domestic use (100 tablets) - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.